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Background: Routine chemotherapy often cannot achieve good therapeutic effects because of multidrug
resistance (MDR). MDR is frequently caused by the elevated expression of the MDR1 gene encoding P-glycoprotein
(P-gp). E2F1 is a frequently overexpressed protein in human tumor cells that increases the activity of the MDR1
promoter, resulting in higher P-gp levels. The upregulation of P-gp might contribute to the survival of tumor cells
during chemotherapy. E2F1 confers anticancer drug resistance; however, we speculate whether E2F1 affects MDR
through other pathways. This study investigated the possible involvement of E2F1 in anticancer drug resistance of
gastric carcinoma in vitro and in vivo.
Methods: A cisplatin-resistant SGC7901/DDP gastric cancer cell line with stable overexpression of E2F1 was
established. Protein expression levels of E2F1, MDR1, MRP, TAp73, GAX, ZEB1, and ZEB2 were detected by western
blotting. The influence of overexpression of E2F1 on anticancer drug resistance was assessed by measuring IC50 of
SGC7901/DDP cells to cisplatin, doxorubicin, and 5-fluorouracil, as well as the rate of doxorubicin efflux, apoptosis, and
cell cycle progression detected by flow cytometry. We determined the in vivo effects of E2F1-overexpression on tumor
size in nude mice, and apoptotic cells in tumor tissues were detected by deoxynucleotidyl transferase-mediated
dUTP-biotin nick end labeling and hematoxylin and eosin staining.
Results: The SGC7901/DDP gastric cancer cell line stably overexpressing E2F1 exhibited significantly inhibited
sensitivity to cisplatin, doxorubicin, and 5-fluorouracil. Flow cytometry confirmed that the percentage of
apoptotic cells decreased after E2F1 upregulation, and that upregulation of E2F1 potentiated S phase arrest of the
cell cycle. Furthermore, upregulation of E2F1 significantly decreased intracellular accumulation of doxorubicin. Western
blot revealed that E2F1 upregulation suppressed expression of GAX, and increased the expression of MDR1, MRP, ZEB1,
TAp73, and ZEB2.
Conclusions: Overexpression of E2F1 promotes the development of MDR in gastric carcinoma, suggesting that E2F1
may represent an efficacious target for gastric cancer therapy.
Keywords: E2F1 transcription factor, Lentiviral vector, Gastric carcinoma, Drug resistance, Murine model* Correspondence: xiaoqiang20050@aliyun.com
2Department of Surgery, The First Affiliated Hospital of Guangxi Medical
University, Nanning, Guangxi Zhuang Autonomous Region 530021, China
Full list of author information is available at the end of the article
© 2014 Yan et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Yan et al. BMC Cancer 2014, 14:904 Page 2 of 10
http://www.biomedcentral.com/1471-2407/14/904Background
Resistance to anti-neoplastic agents is the major cause of
therapy failure, leading to disease recurrence and metasta-
sis. The molecular genetic basis of resistance to cancer ther-
apeutics is generally complex, involving multiple processes
such as drug transport, drug metabolism, DNA repair and
apoptosis [1]. Emerging evidence suggests that the mecha-
nisms of multidrug resistance (MDR) are closely associated
with the overexpression of P-gp encoded by the MDR1
gene. In tumor cells, P-gp acts as a drug efflux pump that
actively transports drugs from the inside to the outside of
cancer cells and thus prevents the intracellular accumula-
tion of anticancer drugs necessary for cytotoxic activity [2].
However, the factors that regulate the chemoresistance of
gastric carcinoma remain poorly understood.
E2F1 is a unique member of the E2F family of proteins
as it is involved in cell cycle progression and apoptosis
induction in response to DNA damage through its cap-
acity to activate p53/p73 death pathways [3,4]. A previ-
ous study reported that deregulated E2F1 acts as a
driving force in melanoma progression and promotes
tumor invasion and metastasis independently from its
other cellular activities. This aggressive behavior of the
transcription factor in malignant cells is partially medi-
ated through the induction of the epidermal growth fac-
tor receptor pathway [5]. Most importantly, E2F1 plays a
critical role in the malignant phenotypes of some can-
cers. Previous studies reported that E2F1 could affect
cell proliferation and apoptosis and that E2F1 may be in-
volved in regulating MDR in some cancers [6,7]. In
addition, E2F1 stimulates the promoter of the MDR1
gene, resulting in increased expression and higher levels
of P-gp, thus possibly contributing to the development
of MDR [8]. Furthermore, its downregulation suppresses
MDR in gastric carcinoma cells in vitro and in vivo [9].
Although this evidence implies that E2F1 is associated
with carcinogenesis and development of MDR, the pre-
cise role of E2F1 in MDR of gastric carcinoma remains
largely unexplored.
To define the role of E2F1 in multidrug-resistant gastric
carcinoma, we generated gastric carcinoma cells that sta-
bly express E2F1 and evaluated changes in IC50, the rate
of doxorubicin efflux, cell cycle, and apoptosis. We also
examined the expression of genes associated with apop-
tosis and multidrug resistance, including GAX, TAp73,
MDR1, MRP, ZEB1, and ZEB2. Moreover, we investigated
the effects of E2F1 upregulation on the growth and
apoptosis of SGC7901/DDP cells in vivo.
Methods
Reagents and drugs
Adriamycin (ADR) (KEYGEN Biotech, China) was di-
luted in phosphate-buffered saline (PBS) (2 mg/ml). Cis-
diamminedichloroplatinum (cisplatin, DDP) (Qilu PharmoCo. Ltd, China) was resuspended in PBS (1 mg/ml) and
stored at −20°C. 5-fluorouracil (5-FU) (KEYGEN Biotech)
was added in solution (25 mg/ml) and stored at room
temperature. E2F1, GAX, TAp73, MDR1, MRP, ZEB1,
ZEB2 and glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) antibodies were obtained from Santa Cruz
Biotechnology (Santa Cruz, CA, USA). All other chemi-
cals were of the highest available commercial grade.
Cell culture
Cisplatin-resistant SGC7901 (SGC7901/DDP) cells were
purchased from KEYGEN Biotech. SGC7901/DDP cells
were cultured in RPMI-1640 (Hyclone) supplemented with
10% fetal bovine serum (FBS) (Hangzhou Sijiqing Biotech,
Co. Ltd, China) and antibiotics (100 U/ml penicillin and
100 mg/ml streptomycin) in a humidified 5% CO2 atmos-
phere at 37.8°C (Thermo). Cisplatin (0.6 μg/mL) was sup-
plemented in the medium for SGC7901/DDP cell culture
to maintain the drug-resistance phenotype.
Establishment of stable cell lines
The PLNCX lentiviral vector (LV-GFP) purchased from
Shanghai Cancer Institute, China was used to construct
the E2F1 overexpression vector. The construction of LV-
E2F1-GFP and transfection of SGC7901/DDP gastric car-
cinoma cells with LV-E2F1-GFP or LV-GFP have been
previously described [9]. SGC7901/DDP cells were seeded
in six-well plates with antibiotic-free medium. The cells
were divided into three groups: E2F1 group (SGC7901/
DDP + E2F1), GFP group (SGC7901/DDP + GFP), and
NC (negative control) group (SGC7901/DDP). After
24 h incubation, cells were infected with the indicated
viral supernatant at a multiplicity of infection of 120 PFU
per cell (MOI = 120), and stably transfected cell lines were
obtained by culturing transfected cells in the presence
of 700 mg/mL G418 (Invitrogen, Carlsbad, CA, USA)
for 2–3 weeks.
Semiquantitative reverse-transcriptase polymerase chain
reaction
Total RNA was isolated using the AxyPrep™ Purification
Kit (Axygen, USA) according to the manufacturer’s in-
structions. The total RNA concentration and quality
were measured with a Nanodrop 2000 micro-volume
spectrophotometer (Thermo Scientific, USA) by absorb-
ance measurements. RNA integrity was analyzed by 2%
agarose gel electrophoresis and ethidium bromide stain-
ing. First-strand cDNA was synthesized from 3000 ng of
total RNA using the RevertAidHMinus First Strand
cDNA synthesis kit (Fermentas, USA) as instructed by
the manufacturer. Real-time PCR (RT-PCR) reactions
were carried out on an Mx3000P real-time PCR system
(Stratagene USA). To create the RT-PCR standard, glyc-
eraldehyde 3-phosphate dehydrogenase (GAPDH) was
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were as follows: E2F1 primer sense 5′-CCC AAC TCC
CTC TAC CCT-3′ and antisense 5′-CTC CCA TCT
CAT ATC CAT CCT G-3′; and GAPDH primer sense
5′-ACC ACA GTC CAT GCC ATC AC-3′ and anti-
sense 5′-TCA CCA CCC TGT TGC TGT A-3′. The
PCR products were checked by agarose gel electrophor-
esis, and the abundance of each mRNA was detected
and normalized to that of GAPDH mRNA.
Western blot, immunoprecipitation and pull-down assays
Cell lysates were prepared in a buffer containing 100 mmol/L
NaCl, 10 mmol/L Tris–HCl (pH 7.6), 1 mmol/L EDTA
(pH 8.0), 1 μg/mL aprotinin, 100 μg/mL phenylmethylsul-
fonyl fluoride, and 1% (v/v) NP-40. After protein quantita-
tion using the Lowery protein assay, equal amounts of
proteins were separated by SDS-PAGE and blotted onto
nitrocellulose membranes by the semi-dry blotting method
using a three-buffer system. The membranes were incu-
bated with a dilution of primary antibodies (anti-E2F1:
1:1500, anti-GAX: 1:3000, anti-TAp73: 1:2000, anti-
MDR1: 1:3000, anti-MRP: 1:1500, anti-ZEB1: 1:1000, anti-
ZEB2: 1:2000), overnight at 4°C. The membrane was washed
with TBST and incubated with a peroxidase-conjugated
secondary antibody (1:1000) (Santa Cruz Biotechnology)
for 1 h. Specific antibody binding was detected using a
chemiluminescence detection system (Pierce, Rockford,
IL, United States), according to the manufacturer’s recom-
mendations. Western blot film was scanned, and the net
intensities of the bands were quantified using Image-
QuanT software (Molecular Dynamics, Sunnyvale, CA,
United States). After development, the membrane was
stripped and reprobed with antibodies against GAPDH
(1:1000) or β-actin (1:1500) to confirm equal sample load-
ing. Immunoprecipitation and GST pull-down assays were
performed as described previously [10].
Cytotoxicity assay
Cytotoxicity was determined by Cell Counting Kit-8
(CCK-8) assay (KEYGEN Biotech, China). Cells were
seeded in 96-well plates in 100 μl RPMI-1640 medium
supplemented with 10% FBS at 5 × 104 cells/well. Cis-
platin (0.6 μg/mL) was added in normal growth medium
supplemented with FBS. After 48 h incubation, 10 μl
CCK-8 reagent was added and culture was continued for
1 h in a humidified atmosphere containing 5% CO2. Ab-
sorbances at 450 nm were measured by a Microplate
Reader (Biotech Company). The relative drug resistance
was analyzed compared with IC50 values.
Measurement of pump rate of doxorubicin by flow
cytometry
Cells were inoculated into six-well plates containing
4 mg/mL doxorubicin and cultured at 37°C for 30 min.Flow cytometry was used to measure the fluorescent in-
tensity of doxorubicin in cells with an excitation wave-
length of 488 nm and emission wavelength of 575 nm.
The cells were then washed twice with fresh culture
medium and incubated with the new medium at 37°C
for 1 h to detect the retained doxorubicin. Subtraction
of the fluorescence retained from the total fluorescence
was the fluorescent index of doxorubicin. The procedure
was repeated three times and an average value was ob-
tained to calculate the pump rate of doxorubicin. The
pump rate of the drug from the cells = (accumulated quan-
tity of doxorubicin – retained quantity of doxorubicin)/
accumulated quantity of doxorubicin.
Apoptosis analysis by flow cytometry
SGC7901/DDP cells (1 × 106) were washed twice with
ice-cold PBS, treated with trypsin, and fixed in cold 70%
ethanol at 4°C for 30 min. The cell pellet was incubated
in a solution containing 10 μl/mL Annexin V-FITC and
10 μl/mL 7-amino-actinomycin D (7-AAD). The cells
were analyzed by flow cytometry using an EPICS XL-MCL
FACScan (Becton-Dickinson, Mountain View, CA, USA).
The data were analyzed with MultiCycle Software for
Windows (Phoenix Flow Systems, San Diego, CA, USA).
Cell cycle analysis by flow cytometry
SGC7901/DDP cells (1 × 106) were washed twice with
ice-cold PBS, treated with trypsin, and fixed in cold 70%
ethanol at 4°C for 30 min. The cell pellet was incu-
bated in a solution containing 50 ng/mL propidium iod-
ide, 0.2 mg/mL RNase, and 0.1% Triton X-100 at room
temperature for 30 min. The cells were analyzed by flow
cytometry as described above.
Effect of LV-E2F1-GFP on promoting MDR of human
gastric carcinoma in vivo
BALB/c 5-week-old male nude mice (Guangxi Animal
Center, Nanning, China) were kept under specific pathogen-
free conditions and tended to in accordance with institu-
tional guidelines. All experimental studies were approved
by the Guangxi Medical University Animal Care and Use
Committee. Approximately 2 × 106 SGC7901/DDP cells
were resuspended in 100 μL PBS, and implanted subcuta-
neously into the flanks of the BALB/c nude mice. The
resulting tumor was named the SGC7901/DDP tumor.
After 7 days, when the SGC7901/DDP tumor measured
3–5 mm in diameter, the mice were randomly divided
into three groups (six mice/per group): E2F1, GFP, and
SGC7901/DDP. The animals were administered an intra-
tumoral injection of LV-E2F1-GFP or LV-GFP at a titer of
5 × 106 TU in 100 μL PBS. Injection of an equal volume of
PBS was used as a negative control (NC). After the first
injection, the animals were re-injected every 2 days. DDP
was administered by intraperitoneal injection at a dose of
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tumors were monitored every day and measured every
2 days with a caliper, and the diameters were recorded.
The tumor volume (TV) was calculated by the formula:
TV =W2 × L/2, where L is the length and W is the width
of the tumor. The relative tumor volume (RTV) was cal-
culated by the formula: RTV =Vt/V0 (V0 is the TV at the
day when the chemicals were given, and Vt is the TV
of subsequent measurement). The animals were sacri-
ficed 34 days after tumor injection and the tumors were
analyzed.
Hematoxylin and eosin staining and deoxynucleotidyl
transferase-mediated dUTP-biotin nick end labeling assay
For hematoxylin and eosin (HE) staining, tumor tissues
were fixed in 4% formaldehyde, dehydrated with an etha-
nol gradient, and embedded in paraffin wax. Tissue
sections were dewaxed and rehydrated according to a
standard protocol, and sections were stained with HE. For
the deoxynucleotidyl transferase-mediated dUTP-biotin
nick end labeling (TUNEL) assay, apoptotic cells in sec-
tions of mouse tumor tissue were detected using an in situ
apoptosis detection kit (KEYGEN, Nanjing, China) as
instructed by the manufacturer. Cells were visualized with a
light microscope (Olympus IX70, Tokyo, Japan). The apop-
totic index was calculated as follows: apoptotic index =
number of apoptotic cells/total number of cells. The in vivo
experiments strictly obeyed the ethical principles and
guidelines for scientific experiments on animals.
Statistical analysis
Data are expressed as mean ± SE. Statistical significance
was determined using χ2 test, Student’s t test, or one-
way analysis of variance (ANOVA). Statistical analyses
were carried out using SPSS version 13.0 (Chicago, IL, USA)
or Origin 7.5 software programs (OriginLab, Northampton,
MA, USA). A value of P < 0.05 was considered statistically
significant.
Results
Upregulation of E2F1 is associated with development of
MDR in gastric carcinoma
To examine the relationship between upregulation of E2F1
and acquisition of MDR in gastric carcinoma, we estab-
lished gastric carcinoma cells that stably overexpressed
E2F1. Transfection of LV-E2F1-GFP into SGC7901/
DDP cells led to marked enhancement of E2F1 mRNA
(Figure 1A) and protein expression (Figure 1C). Densi-
tometry analysis showed that E2F1 mRNA (Figure 1B)
and protein (Figure 1D) levels in the E2F1 group were ap-
proximately 3- and 9-fold higher, respectively, than those
in the GFP and NC groups (P < 0.05). There were no dif-
ferences in E2F1 levels between GFP and NC groups.
These results confirmed that the SGC7901/DDP cellsstably transfected with LV-E2F1-GFP showed upregulation
of E2F1 mRNA and protein expression.
We next examined the effects of LV-E2F1-GFP expres-
sion on the drug sensitivity of gastric carcinoma cells.
Although our SGC7901/DDP cell line was selected
under culture with the single anticancer drug cisplatin,
these cells also displayed resistance to other anticancer
drugs. CCK-8 assay was used to detect the sensitivity
of cells to one P-gp-related drug (doxorubicin) and two
P-gp-non-related drugs (5-FU and cisplatin). As shown in
Figure 2A and Table 1, the cells transfected with LV-E2F1-
GFP exhibited significantly increased IC50 values for cis-
platin, doxorubicin and 5-fluorouracil compared with the
GFP and NC groups (P < 0.05). These data indicate that
E2F1 upregulation is associated with the MDR phenotype
in gastric carcinoma.
Effects of LV-E2F1-GFP on pump rate of doxorubicin
We proposed that upregulation of E2F1 promoted drug
efflux in gastric carcinoma in vitro. To test this hypoth-
esis, intracellular drug accumulation and retention were
evaluated using doxorubicin as a probe that can be
detected by flow cytometry. Doxorubicin is a common sub-
strate for P-gp and MRP1, which are involved in well-
characterized mechanisms of MDR [11]. As shown in
Figure 2B, compared with the GFP and NC groups, the
E2F1 group exhibited significantly decreased accumula-
tion and retention of doxorubicin, as well as a higher re-
leasing index of doxorubicin (Figure 2C) (P < 0.05).
LV-E2F1-GFP inhibits apoptosis in the cisplatin-resistant
gastric carcinoma SGC7901/DDP cells
Many chemotherapeutic agents exert anticancer activity
by inducing apoptosis. Most chemotherapeutic agents
applied in the treatment of hematologic malignancies
can induce apoptosis, but MDR tumor cells are generally
resistant to apoptosis induction [12]. Therefore, we investi-
gated the apoptosis index in cisplatin-resistant gastric car-
cinoma cells expressing LV-E2F1-GFP. Cells were stained
with Annexin V PE and 7-AAD and subsequently analyzed
by flow cytometry. The dual parameter fluorescent dot
plots present the viable cells in the lower-left quadrant and
the apoptotic cells in the right quadrant. Compared with
the GFP and NC groups, the E2F1 group exhibited a sig-
nificantly decreased apoptosis index (5.71% ± 0.86% in
E2F1 group compared with 12.04% ± 2.18% and 12.65% ±
1.95% in the GFP and NC groups, respectively; P < 0.001).
The experiments were repeated three times with three
replicates for each group (Figure 2D and E).
We next used flow cytometry to determine whether pro-
motion of MDR by LV-E2F1-GFP in SGC7901/DDP cells
was mediated, at least in part, through an effect on cell
cycle progression (Figure 2F). We found that the number
of cells in S phase in the E2F1 group was markedly
Figure 1 E2F1 mRNA and protein expressions after gene transfection in SGC7901/DDP cells. A: Expression level of E2F1 mRNA was
determined by semiquantitative reverse-transcriptase polymerase chain reaction; B: mRNA results are expressed as the ratio of E2F1 to glyceraldehyde
3-phosphate dehydrogenase (GAPDH); C: Expression level of E2F1 protein was determined by western blotting; D: Western blotting results
are expressed as the ratio of optical density of E2F1 bands to GAPDH bands. All values are mean ± SE. *P < 0.05 for E2F1 group versus
GFP group and negative control (NC) group.
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NC groups (23.74% ± 4.74% and 22.72% ± 3.15%, respect-
ively; P < 0.001). Furthermore, the cells in G1 phase were
decreased in the E2F1 group (51.33% ± 2.81%) compared
with the GFP and NC groups (62.22% ± 3.46% and
65.71% ± 5.00%, respectively; P < 0.001). The experiments
were repeated three times with three replicates for each
group. Together these data indicate that overexpression of
E2F1 in SGC7901/DDP cells induced a cell cycle arrest in
S phase.
LV-E2F1-GFP influenced the expression of MDR1, MRP,
ZEB1, ZEB2, GAX, and TAp73
To investigate the mechanism by which LV-E2F1-GFP
induces MDR in SGC7901/DDP cells, we evaluated the
expression levels of several well-known regulators of apop-
tosis (Caspase-9, Caspase-3, p53, ZEB1, ZEB2, GAX, and
TAp73) and several MDR-related proteins (MDR1, MRP,
mTOR and HIF-1α) by western blot. The expression level
of GAX protein in the E2F1 group was lower than that
in the GFP and NC groups (P < 0.05), while the levels
of MDR1, MRP, ZEB1, ZEB2 and TAp73 were higher
in the E2F1 group than those in the GFP and NC groups
(Figure 3A and B).
To better understand the function of E2F1, we per-
formed a yeast two-hybrid screen using E2F1 as the bait.The two-hybrid results identified MRP as an E2F1-
interacting protein. To confirm physiological binding,
we performed reciprocal immunoprecipitation assays in
lysates from the E2F1 stably expressing gastric adenocar-
cinoma cells and confirmed interaction between endogen-
ous E2F1 and MRP (Figure 3C and D). Furthermore, in
pull-down assays using purified proteins, 6xHis-tagged
MRP (His-MRP) bound to GST-E2F1, but not GST alone
(Figure 3E), confirming MRP as an E2F1-interacting pro-
tein and that E2F1 and MRP associate with each other
directly.
Animal studies
We next examined the effect of LV-E2F1-GFP on the
growth of SGC7901/DDP cells in vivo. We implanted
SGC7901/DDP cells subcutaneously into the flanks of
the BALB/c nude mice to generate SGC7901/DDP tu-
mors. After 7 days, the mice were randomly divided into
three groups and administered an intratumoral injection
of LV-E2F1-GFP, LV-GFP or PBS as a negative control
(NC). Evaluation of expression levels of E2F1 in vivo by
semiquantitative RT-PCR and western blotting confirmed
that the mRNA (Figure 4A) and protein (Figure 4B) ex-
pression levels of E2F1 in the E2F1 group were higher
than that in the GFP group. Three weeks after implant-
ation, the RTV was significantly higher in the E2F1 group
Figure 2 Effect of upregulation of E2F1 on cell pump rate of doxorubicin, cell cycle, and apoptotic rate in SGC7901/DDP cells. A: IC50
values for anticancer drugs in SGC7901/DDP cells; B, C: Pump rate of doxorubicin in SGC7901/DDP cells stably expressing E2F1 was analyzed
by flow cytometry; D, E: Percentages of apoptotic cells were analyzed by flow cytometry. F: Cell cycle of SGC7901/DDP cells after E2F1 gene
transfection was analyzed by flow cytometry. All values are mean ± SE. *P < 0.05 for E2F1 group versus GFP group and NC group.
Yan et al. BMC Cancer 2014, 14:904 Page 6 of 10
http://www.biomedcentral.com/1471-2407/14/904than in the NC and GFP groups (P < 0.05) (Figure 4C). As
shown in Figure 4D and E, the percentage of apoptotic
tumor cells was lower in the E2F1 group at 8.82% ± 1.81%,
compared with 19.21% ± 2.3% in the GFP group and
22.13% ± 4.6% in the NC group (P < 0.05).Discussion
Gastric carcinoma is one of the most common malignancies
of humans, with a high incidence in China. While surgical
resection remains the primary treatment, chemotherapy is
sometimes beneficial in patients with advanced gastric







E2F1 1.52 ± 0.15* 5.22 ± 0.13* 3.52 ± 0.15*
GFP 0.53 ± 0.09 3.85 ± 1.01 2.26 ± 0.38
NC 0.61 ± 0.12 4.12 ± 0.72 2.52 ± 0.83
IC50 values were evaluated by CCK-8 assay. Each experiment was conducted
in triplicate. Data are expressed as means±SD of four independent experiments. One-
way analysis of variance followed by Dunnett’s multiple comparison test revealed
statistical differences of *P<0.05 for the E2F1 group versus the GFP group and NC group.
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often thwarted by simultaneous resistance of tumor cells
to multiple cytotoxic drugs, known as MDR. MDR cur-
rently remains the major obstacle to successful cancer
chemotherapy in the clinic [13]. The precise molecularFigure 3 Overexpression of E2F1 decreased GAX and TAp73, and increase
expression levels of MDR1, MRP, TAp73, GAX, ZEB1, and ZEB2 were determined by
blot analysis of endogenous E2F1 and MRP interaction in SGC7901/DDP cells. E: Inmechanisms underlying MDR remain obscure. However,
increasing evidence supports the view that mechanisms
involved in MDR include decreased drug accumulation
in tumor cells, altered intracellular drug distribution,
increased detoxification, diminished drug-target inter-
action, increased DNA repair, altered cell cycle regula-
tion, and uncoupled pathways linking cellular damage
with apoptosis [14,15].
E2F1 is a member of the E2F family that functions in
cell cycle progression and apoptosis induction in re-
sponse to DNA damage. Recently, we showed that
deregulated E2F1 acts as a driving force in gastric car-
cinoma progression and promotes tumor invasion and
metastasis independently from its other cellular activ-
ities. Recent evidence, however, showed that high levelsd MDR1, MRP, ZEB1, and ZEB2 protein expression. A, B: Protein
western blotting. C, D: Reciprocal immunoprecipitation assays and western
vitro pull-down assays using 6xHis-tagged MRP (His-MRP), GST-E2F1 and GST.
Figure 4 Apoptosis of LV-E2F1-GFP cells and tumors in nude mice in vivo. A: mRNA expression level of E2F1 was determined by
semiquantitative reverse-transcriptase polymerase chain reaction; B: E2F1 protein expression was determined by western blotting; C: Relative
tumor volume (RTV) of nude mice in each group is presented. Each time point represents the mean RTV for each group. D: Tumor cells were evaluated
by HE staining and TUNEL assay (× 400); E: Percentage of apoptotic cells was analyzed by TUNEL assay. All values are mean ± SE. *P < 0.05 for E2F1
group versus GFP group and NC group.
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turn, controls E2F1 accumulation. Finally, drug resist-
ance associated with this genetic signature is mediated
by removing the inhibitory effect of miR-205 on the
expression of Bcl-2 and the ATP-binding cassette
transporters A2 and A5 related to MDR and malignant
progression [16].
One major form of resistance to chemotherapy has
been correlated to two molecular pumps, including P-gp,encoded by the MDR1 gene, and MDR protein 1 (MRP1).
MDR1 mediates a well-characterized form of drug resist-
ance that is primarily due to overexpression of a P-gp
efflux pump [17]. This efflux pump belongs to the ATP-
binding cassette (ABC) transporter superfamily and is
capable of effluxing many different chemotherapeutic
agents, hence the MDR. The resistance is thus due to
decreased drug accumulation. E2F1 downregulation has been
shown to reverse this form of drug resistance by blocking
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decreased drug accumulation is MRP1-mediated drug re-
sistance. MRP1 also belongs to the ABC transporter super-
family; however, this efflux pump most likely transports
glutathione-conjugated drugs [18]. Our results showed that
MDR1 and MRP expression were increased when E2F1
was upregulated. This indicates that E2F1 confers anti-
cancer drug resistance by targeting ABC transporter family
members in gastric carcinoma.
In addition to the P-gp and MRP1 signaling pathways,
apoptosis also mediates the killing effects of anticancer
drugs, which is an important cause of MDR [12]. ZEB1
is a DNA-binding protein that binds to six consensus
boxes located within the TAp73 promoter, resulting in the
repression of TAp73 transcription [19]. TAp73 is a struc-
tural homolog of the p53 tumor suppressor. However,
unlike p53, TAp73 is rarely mutated in human tumors and
instead is frequently overexpressed. Most studies have
shown that TAp73 acts as an apoptosis promoter [20].
Methyl methanesulfonate (MMS) has been shown to
induce apoptosis in various cell types through p53/
p73-dependent pathways. However, pharmacological and
genetic blockade of p53/p73 functions still results in similar
or delayed sensitivity to MMS treatment, suggesting the
presence of p53/p73-independent apoptotic mechanisms
[21]. This may explain the finding that overexpression
of E2F1 decreased the percentage of apoptotic cells, thus
apoptosis of SGC7901/DDP cells may occur through
p53/p73-independent pathways. In addition, growth arrest-
specific homeobox (GAX, also known as MEOX2) is
a transcription factor originally isolated from vascular
smooth muscle. GAX is downregulated by mitogens and
upregulated by growth arrest signals, and is also expressed
in endothelial cells, where it plays an important role in
inhibiting endothelial cell phenotypic changes and the
process of angiogenesis [22,23]. Knowing that ZEB2, a
direct target of miR-221 and whose downregulation by
miR-221 leads to the upregulation of GAX expression,
acts primarily as a transcriptional repressor, Chen et al.
identified two ZEB2 binding sites in the GAX promoter
that modulate the ability of ZEB2 to downregulate GAX
promoter activity [24,25]. Our results showed that the
E2F1-overexpression lentiviral vector induced the up-
regulation of ZEB1, ZEB2, and TAp73 expression and
downregulation of GAX. This could explain the decrease
of apoptotic cells after E2F1 upregulation in SGC7901/
DDP cells.
Conclusions
In summary, we demonstrated that upregulation of E2F1
significantly inhibited the sensitivity of SGC7901/DDP
gastric adenocarcinoma cells to anticancer drugs, and
decreased the percentage of apoptotic cells. Upregula-
tion of E2F1 in gastric adenocarcinoma cells potentiatedS phase arrest of the cell cycle. Furthermore, our cell line
stably expressing E2F1 showed significantly decreased
intracellular accumulation of doxorubicin. We conclude
that upregulation of E2F1 promotes the development of
MDR in gastric carcinoma via inhibition of GAX gene
expression, and increased expression of MDR1, MRP, and
TAp73. Finally, our observations suggest that E2F1 might
serve as a molecular target for the therapy of MDR in
gastric carcinoma. We speculate that targeting this gene
might aid in the treatment of gastric carcinoma by inhibit-
ing MDR.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
XQ and XYB designed the research; YLH performed the research; WWY, CWL,
ZXS provided the reagents; YLH analyzed the data and wrote the paper. All
authors read and approved the final manuscript.
Acknowledgments
The work was supported by the Natural Science Foundation of China,
No. 81060201 and No. 81160289; Natural Science Foundation of Guangxi,
No. 2013GXNSFAA019163; and the Key Health Science Foundation of
Guangxi, No. 1298003-2-6 and No. 14124004-1-9.
Author details
1Department of Gastrointestinal Surgery, Affiliated Tumor Hospital of Guangxi
Medical University, Nanning, Guangxi Zhuang Autonomous Region 530021,
China. 2Department of Surgery, The First Affiliated Hospital of Guangxi
Medical University, Nanning, Guangxi Zhuang Autonomous Region 530021,
China. 3Department of Anesthesiology, The First Affiliated Hospital of
Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region
530021, China.
Received: 4 August 2014 Accepted: 27 November 2014
Published: 3 December 2014
References
1. Dai Z, Huang Y, Sadee W: Growth factor signaling and resistance to
cancer chemotherapy. Curr Top Med Chem 2004, 4:1347–1356.
2. Wang JH, Du JP, Li SJ, Zhai LP, Yang XY, Wang ZH, Wu ZT, Han Y:
Octarepeat peptides of prion are essential for multidrug resistance in
gastric cancer cells. J Dig Dis 2012, 13:143–152.
3. Halaban R, Cheng E, Smicun Y, Germino J: Deregulated E2F transcriptional
activity in autonomously growing melanoma cells. J Exp Med 2000,
191:1005–1016.
4. Tuve S, Wagner SN, Schittek B, Putzer BM: Alterations of DeltaTA-p 73
splice transcripts during melanoma development and progression. Int J
Cancer 2004, 108:162–166.
5. Alla V, Engelmann D, Niemetz A, Pahnke J, Schmidt A, Kunz M, Emmrich S,
Steder M, Koczan D, Putzer BM: E2F1 in melanoma progression and
metastasis. J Natl Cancer Inst 2010, 102:127–133.
6. Han S, Park K, Bae BN, Kim KH, Kim HJ, Kim YD, Kim HY: E2F1 expression
is related with the poor survival of lymph node-positive breast cancer
patients treated with fluorouracil, doxorubicin and cyclophosphamide.
Breast Cancer Res Treat 2003, 82:11–16.
7. Lu D, Xiao Z, Wang W, Xu Y, Gao S, Deng L, He W, Yang Y, Guo X, Wang X:
Down regulation of CIAPIN1 reverses multidrug resistance in human
breast cancer cells by inhibiting MDR1. Molecules 2012, 17:7595–7611.
8. Andorfer P, Rotheneder H: Regulation of the MDR1 promoter by E2F1
and EAPP. FEBS Lett 2013, 587:1504–1509.
9. Yan LH, Wang XT, Yang J, Kong FB, Lian C, Wei WY, Luo W, Xie YB, Xiao Q:
Reversal of multidrug resistance in gastric cancer cells by E2F-1
downregulation in vitro and in vivo. J Cell Biochem 2014, 115:34–41.
10. Du W, Jiang P, Li N, Mei Y, Wang X, Wen L, Yang X, Wu M: Suppression of
p53 activity by Siva1. Cell Death Differ 2009, 16:1493–1504.
Yan et al. BMC Cancer 2014, 14:904 Page 10 of 10
http://www.biomedcentral.com/1471-2407/14/90411. Okada T, Tanaka K, Nakatani F, Sakimura R, Matsunobu T, Li X, Hanada M,
Nakamura T, Oda Y, Tsuneyoshi M, Iwamoto Y: Involvement of P-glycoprotein
and MRP1 in resistance to cyclic tetrapeptide subfamily of histone
deacetylase inhibitors in the drug-resistant osteosarcoma and
Ewing's sarcoma cells. Int J Cancer 2006, 118:90–97.
12. Zhang JY, Lin MT, Yi T, Tang YN, Fan LL, He XC, Zhao ZZ, Chen HB:
Apoptosis Sensitization by Euphorbia Factor L1 in ABCB1-Mediated
Multidrug Resistant K562/ADR Cells. Molecules 2013, 18:12793–12808.
13. Chuman Y, Sumizawa T, Takebayashi Y, Niwa K, Yamada K, Haraguchi M,
Furukawa T, Akiyama S, Aikou T: Expression of the multidrug-resistance-
associated protein (MRP) gene in human colorectal, gastric and non-small-
cell lung carcinomas. Int J Cancer 1996, 66:274–279.
14. Gillet JP, Gottesman MM: Mechanisms of multidrug resistance in cancer.
Methods Mol Biol 2010, 596:47–76.
15. Martinez-Lacaci I, Garcia Morales P, Soto JL, Saceda M: Tumour cells
resistance in cancer therapy. Clin Transl Oncol 2007, 9:13–20.
16. Alla V, Kowtharapu BS, Engelmann D, Emmrich S, Schmitz U, Steder M,
Putzer BM: E2F1 confers anticancer drug resistance by targeting ABC
transporter family members and Bcl-2 via the p73/DNp73-miR-205
circuitry. Cell Cycle 2012, 11:3067–3078.
17. Minchinton AI, Tannock IF: Drug penetration in solid tumours. Nat Rev
Cancer 2006, 6:583–592.
18. Cole SP: Targeting multidrug resistance protein 1 (MRP1, ABCC1): past,
present, and future. Annu Rev Pharmacol Toxicol 2014, 54:95–117.
19. Fontemaggi G, Gurtner A, Strano S, Higashi Y, Sacchi A, Piaggio G, Blandino G:
The transcriptional repressor ZEB regulates p73 expression at the crossroad
between proliferation and differentiation. Mol Cell Biol 2001, 21:8461–8470.
20. Du W, Jiang P, Mancuso A, Stonestrom A, Brewer MD, Minn AJ, Mak TW,
Wu M, Yang X: TAp73 enhances the pentose phosphate pathway and
supports cell proliferation. Nat Cell Biol 2013, 15:991–1000.
21. Jiang Y, Zhang XY, Sun L, Zhang GL, Duerksen-Hughes P, Zhu XQ, Yang J:
Methyl methanesulfonate induces apoptosis in p53-deficient H1299 and
Hep3B cells through a caspase 2-and mitochondria-associated pathway.
Environ Toxicol Pharmacol 2012, 34:694–704.
22. Gorski DH, Leal AJ: Inhibition of endothelial cell activation by the
homeobox gene Gax. The J Surg Res 2003, 111:91–99.
23. Zhou P, Jiang W, Wu L, Chang R, Wu K, Wang Z: miR-301a is a candidate
oncogene that targets the homeobox gene Gax in human hepatocellular
carcinoma. Dig Dis Sci 2012, 57:1171–1180.
24. Chen Y, Banda M, Speyer CL, Smith JS, Rabson AB, Gorski DH: Regulation of
the expression and activity of the antiangiogenic homeobox gene GAX/MEOX2
by ZEB2 and microRNA-221. Mol Cell Biol 2010, 30:3902–3913.
25. van Grunsven LA, Michiels C, Van de Putte T, Nelles L, Wuytens G,
Verschueren K, Huylebroeck D: Interaction between Smad-interacting
protein-1 and the corepressor C-terminal binding protein is
dispensable for transcriptional repression of E-cadherin. J Biol
Chem 2003, 278:26135–26145.
doi:10.1186/1471-2407-14-904
Cite this article as: Yan et al.: Overexpression of E2F1 in human gastric
carcinoma is involved in anti-cancer drug resistance. BMC Cancer
2014 14:904.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
